近日， FineHeart 宣布，已完成 C 轮融资首轮交割 ，本轮首期募集资金 4,070 万美元（约合人民币 2.8亿 ） ，用于推进其用于心力衰竭治疗的下一代植入式装置 FlowMaker® 的临床与产业化进程。 在本轮融资完成后，FineHeart 通过私募资本与欧洲公共资金的组合，累计获得约 9,660 万美元 的资金支持。 此次融资不仅为公司后续研发与商业化提供直接资金保障，也成为撬动 IPCEI Tech4Cure 项目公共资金的重要杠杆。根据披露，FineHeart 作为该项目的核心参与方 之一，还将获得 4,800 万欧元 的非稀释性资助，用于支撑欧洲有源植入式医疗器械（AIMD）关键技术体系的建设。 # 聚焦心衰治疗 ：下 一代植入式 装置的技术路径 # 市场背景：LVA D 体 系之 外的另一 种可能 FineHeart 的核心产品 FlowMaker ，是一款面向重度心力衰竭患者的 全植入式心输出量加速装置 。与当前主流的左心室辅助装置（LVAD）不同，FlowMaker 的设 计目标并非完全替代心脏泵血功能，而是 与心脏自身收缩节律协同工作 ，在保留原生心功能的前提下提供辅助支持。 ...

在医疗器械行业，无论是企业招聘，还是个人职业选择，真正的风险往往不是"招不到人"或"找不到工作"，而是—— 双方看似合适，却难以长期共存。 不少合作，开始得很快，结束得也很快。 就像一场"闪婚闪离"。 那么，企业与候选人，究竟该如何判断彼此是否真正适合长期合作？ 哪些信号在面试阶段就已经存在，却常被忽略？ 哪些误判，在入职后才逐渐显现？ 哪些结构性错位，即使双方都优秀，也注定难以匹配？ 本次分享，我们邀请一位长期服务于医疗器械行业的资深猎头，从多年真实招聘与入职案例出发，围绕"企业与候选人的双向匹配"，系统讨论： 分享嘉宾： 方超，Powerlinks管理合伙人，专注医疗器械领域招聘16年，助力逾百家500强外企、国内上市公司和各阶段初创公司的全模块人员搭建和配置。 活动时间： 2026年1月21日星期三上午10:30，苏州，工业园区 活动规模：20人左右 报名方式：粘贴链接到浏览器填写，或点击文末阅读原文 https://hdxu.cn/1Eftz 企业如何判断一个候选人是否真正适合自身阶段与文化 候选人如何识别一家企业是否适合自己长期发展 面试中最容易产生的双向误判 不同企业阶段下，对人才的真实需求差异 ...

企业简介，看起来只是几段文字，但真正写好它，往往意味着： 你对公司战略是否清楚， 对产业位置是否有判断， 对未来方向是否有认知， 也是否理解同行与市场在看什么。 因为企业简介， 不仅是"我是谁"， 更隐含着： 本次活动，我们针对医疗器械公司，希望讨论清楚三件事 1. 企业简介，写给谁看？ 不同阅读对象，关注点完全不同： 企业简介首先是一种 认知工具 ，而不是资料堆砌。 我在产业中的位置 我未来可能走向哪里 投资人关心：对标对象、成长空间、退出路径 媒体关心：行业位置、故事价值 销售关心：是否好记、好讲 合作方关心：你能提供什么价值 2. 不同资料中的企业简介，本质是不同功能的传播工具 但现实中，我们常常用同一套写法应对所有场景。 3. 企业简介如何写，才能被记住？ 我们将重点讨论： 例如： 在融资BP中，如果企业简介不能帮助投资人迅速找到二级市场对标对象，就很难判断企业未来的市值空间与 退出路径；而投资人也需要一套清晰、好讲的逻辑，向LP解释这是一家怎样的公司。 这些判断，往往就发生在企业简介的几段文字中。 主题 企业简介，其实不简单 —— 一次关于"企业如何被理解"的传播讨论 官网企业简介：第一认知入口 融 ...

Core Viewpoint - The article discusses the recent results of the "3+N" alliance procurement project for hemostatic materials in the Beijing-Tianjin-Hebei region, highlighting the shift in medical device procurement policies towards higher value products and the opportunities for domestic companies with innovative technologies [1][3]. Group 1: Procurement Policy Changes - The volume-based procurement policy is significantly altering the landscape of the medical device market, particularly in the hemostatic materials sector, where there is a growing demand for efficient, safe, and user-friendly innovative products [2][3]. - The recent procurement project indicates a trend towards higher value products, moving away from a focus solely on low-cost consumables to include clinical value and innovation in the evaluation criteria [3][5]. Group 2: Successful Bids and Innovations - The successful bid of Maipu Medical's Ji Su Ting® absorbable regenerated oxidized cellulose hemostatic product is attributed to its unique material properties and clinical applicability [6][9]. - The product is designed for various surgical procedures, demonstrating superior performance in promoting platelet aggregation and reducing surgical time and complication risks compared to traditional materials [8][9]. Group 3: Industry Trends and Future Outlook - The selection of Ji Su Ting® reflects the broader trend of domestic high-end hemostatic materials gaining traction in the market, as domestic companies enhance their R&D capabilities and clinical trial data [9][10]. - The volume-based procurement policy provides a pathway for innovative products to enter hospitals more rapidly, allowing for the accumulation of clinical usage data and feedback for further optimization [9][10]. - Maipu Medical plans to continue investing in R&D to optimize existing product performance and expand its product line to meet diverse clinical needs [9][10].

Group 1: Acquisition Details - Boston Scientific announced a definitive agreement to acquire Penumbra for $374 per share, corresponding to an enterprise value of approximately $14.5 billion [2] - The transaction will be completed through a combination of cash and stock, with cash accounting for about 73% and stock for about 27% [2] - The cash portion will be financed through internal funds and new debt, with the deal expected to close in 2026 pending shareholder approval [2] Group 2: Penumbra's Business Overview - Penumbra, based in Alameda, California, focuses on thrombosis-related diseases and neurovascular interventions, with a projected revenue of approximately $1.4 billion for 2025, reflecting a year-on-year growth of about 17% [3] - The company's products address various critical conditions, including acute ischemic stroke, pulmonary embolism, deep vein thrombosis, acute limb ischemia, myocardial infarction, and aneurysm-related interventions [3] Group 3: Technological Strategy - Penumbra's strategy centers on mechanical thrombectomy rather than drug thrombolysis or energy-assisted methods, with its most recognizable technology being the Computer-Assisted Vacuum Thrombectomy (CAVT) system [4] - The Lightning Bolt and Lightning Flash product series enhance operational consistency and controllability in complex clinical scenarios, such as pulmonary embolism and peripheral deep vein thrombosis [6] Group 4: Complementary Product Lines - Penumbra has developed a peripheral embolization system for rapid blood flow intervention in scenarios requiring hemorrhage control or vascular occlusion, complementing its thrombectomy systems [7] - This dual product line allows Penumbra to address both "thrombus removal" and "blood flow blockage" needs, enhancing its market position [7] Group 5: Industry Context - The acquisition of Penumbra is part of a broader trend of adjacent expansion in the vascular intervention field by large medical device companies, focusing on extending existing customer bases and clinical pathways [13] - Boston Scientific previously established a market presence in the peripheral vascular and pulmonary embolism sectors through its EKOS product line, which utilizes ultrasound-assisted thrombolysis [14][16] Group 6: Strategic Implications - The acquisition is viewed as a means to complement Boston Scientific's existing product offerings rather than replace them, as it addresses different stages in the stroke treatment continuum [16][18] - The recent acquisition of Inari Medical by Stryker has raised the profile of the peripheral thrombosis and pulmonary embolism markets, leading to a reassessment of growth potential and valuation for companies like Penumbra [19][20]

Core Viewpoint - Qingfeng Biotech has completed a multi-million Pre-A round financing, led by Baiyun Fund, to advance its AI+ laboratory automation initiatives, including capacity expansion and the development of AI models [1] Market Status - The laboratory automation market is entering a stable growth phase, with AI becoming a key driver. The global market size is projected to reach approximately $8-8.3 billion in 2024, $9 billion in 2025, and $14-18 billion by 2030, maintaining a compound annual growth rate (CAGR) of 7-9% [2] - In China, the AI-related laboratory market is expected to grow from approximately 15-20 billion RMB in 2024 to 20-25 billion RMB in 2025, and reach 50-60 billion RMB by around 2030, with a CAGR of 15-20% [4] Company Overview - Qingfeng Biotech, established in 2018, focuses on the R&D, production, and sales of life science automation equipment and integrated platforms. The company emphasizes system-level design and platform delivery capabilities rather than just single-device solutions [5] - The OutStanding large-scale automated pipetting workstation integrates high flexibility, modularity, and standardization, supporting multiple life science applications. It has successfully bid for a project valued at nearly 2 million RMB per unit, competing with imported brands [5] AI Integration - Qingfeng Biotech is enhancing its laboratory automation applications by integrating AI capabilities, focusing on the development of BioFlow AI and Supervisor AI models for experimental process management and data-driven optimization [6] - The trend of "AI+ smart laboratories" is evolving from single-point algorithms to core capabilities throughout the entire experimental process, aiming to reduce human error and improve operational efficiency [7] Post-Financing Strategy - The company's development focus is shifting from individual equipment to a systematic construction of "automation platforms + AI capabilities." The financing will be directed towards capacity, algorithms, application centers, and platform capabilities, highlighting the importance of scalable delivery and long-term technological evolution [8]

在医疗器械行业，无论是企业招聘，还是个人职业选择，真正的风险往往不是"招不到人"或"找不到工作"，而是—— 双方看似合适，却难以长期共存。 不少合作，开始得很快，结束得也很快。 就像一场"闪婚闪离"。 那么，企业与候选人，究竟该如何判断彼此是否真正适合长期合作？ 哪些信号在面试阶段就已经存在，却常被忽略？ 哪些误判，在入职后才逐渐显现？ 哪些结构性错位，即使双方都优秀，也注定难以匹配？ 本次分享，我们邀请一位长期服务于医疗器械行业的资深猎头，从多年真实招聘与入职案例出发，围绕"企业与候选人的双向匹配"，系统讨论： 这不是招聘技巧或求职技巧分享， 方超，Powerlinks管理合伙人，专注医疗器械领域招聘16年，助力逾百家500强外企、国内上市公司和各阶段初创公司的全模块人员搭建和配置。 活动时间： 2026年1月21日星期三上午10:30，苏州，工业园区 活动规模：20人左右 报名方式：粘贴链接到浏览器填写，或点击文末阅读原文 https://hdxu.cn/1Eftz 企业如何判断一个候选人是否真正适合自身阶段与文化 候选人如何识别一家企业是否适合自己长期发展 面试中最容易产生的双向误判 不同企业阶段下，对 ...

Core Viewpoint - The appointment of Mark R. Bezjak as Group Vice President of the Americas Regional Commercial Organization at Dentsply Sirona reflects a strategic alignment with the company's focus on enhancing market service and growth execution in the Americas region [1][5][8]. Group 1: Mark Bezjak's Career Background and Responsibilities - Mark Bezjak has over 20 years of experience in the medical device industry, primarily focusing on commercial and market execution rather than clinical technology or product development [2][3]. - He has held several senior leadership positions at Zimmer Biomet, including President of the Americas, where he oversaw commercial operations, channel management, and regional market strategy execution across North America and Latin America [3]. - Bezjak's expertise includes leading complex organizations, developing commercial strategies, and implementing market solutions with a strong emphasis on customer-centric execution and team building [3]. Group 2: Executive Evaluation - Dentsply Sirona's executives have expressed confidence in Bezjak's appointment, highlighting his commercial expertise, customer-oriented mindset, and ability to build high-performance teams as essential for executing the company's growth strategy [5]. - The company views Bezjak's leadership as a critical asset for enhancing market service and driving growth in the Americas [5]. Group 3: Company Background - Zimmer Biomet, founded in 1927, is a significant player in the orthopedic medical device sector, specializing in joint replacement and rehabilitation equipment [6]. - Dentsply Sirona, headquartered in Charlotte, North Carolina, is a global leader in dental equipment and technology, focusing on dental imaging, CAD/CAM systems, and implant solutions [6]. - The two companies operate in distinct segments, with Zimmer Biomet concentrating on orthopedic implants and robotics, while Dentsply Sirona focuses on dental clinical equipment and digital solutions [6]. Group 4: Conclusion - Bezjak's transition to Dentsply Sirona signifies a match between his career trajectory and the company's current emphasis on commercial execution and organizational management in the Americas [8]. - The appointment is seen as a clear and routine management adjustment aimed at enhancing execution capabilities within the company [8].

Core Insights - The JPM Health Conference highlighted a shift in focus among major medical device companies from investment narratives to growth execution, emphasizing the importance of mergers and acquisitions, AI integration, and organizational restructuring for future growth [2][4]. Medtronic - Medtronic's leadership emphasized a transition to a "growth execution phase," with a focus on accelerating growth through existing technologies and strategic acquisitions, particularly smaller tuck-in acquisitions [6][7]. - The company plans to launch its Hugo surgical robot system in the U.S. in 2026, targeting soft tissue surgery as a key growth area, and sees significant market potential in cardiac electrophysiology and renal denervation [7][8]. - Medtronic aims for mid-to-high single-digit revenue growth in 2026, driven by advancements in ASC penetration and AI-enabled surgical planning [8]. Boston Scientific - Boston Scientific reported over 10% revenue growth for three consecutive years, driven by core products like PFA and WATCHMAN, with a focus on maintaining high growth in the electrophysiology market [10][11]. - The company aims to enhance the overall adoption of arrhythmia treatments and expand its product offerings, including the FARAPOINT catheter, to new indications [11]. - Boston Scientific's growth strategy includes targeting outpatient surgical centers and advancing its clinical pipeline with new innovations [11]. Stryker - Stryker's CEO highlighted the importance of mergers and acquisitions, particularly in orthopedics and neurology, while focusing on enhancing the Mako robotic platform [12][14]. - The company expects to achieve 7%-9% revenue growth in 2026, with a strong emphasis on outpatient surgical centers as a significant growth driver [14]. Johnson & Johnson - Johnson & Johnson's CEO indicated a return to fundamentals, with a focus on execution and long-term growth, planning to invest approximately $55 billion in new facilities and R&D, particularly in MedTech [15][17]. - The company is preparing for regulatory milestones for its Ottava surgical robot system, with significant contributions expected post-2028 [17][18]. - J&J's strategy includes strategic investments in robotic systems to enhance its outpatient surgical capabilities [18]. Intuitive Surgical - Intuitive Surgical's focus remains on expanding its da Vinci system and integrating AI functionalities to improve surgical efficiency [19][20]. - The company anticipates a competitive landscape in soft tissue robotics but believes its established ecosystem provides a competitive advantage [20]. - Intuitive expects revenue growth of 12%-15% in 2026, driven by increased surgical volumes and international market expansion [20]. Alcon - Alcon is committed to innovation in eye health, focusing on surgical and vision care segments, with a significant emphasis on enhancing operational efficiency [22][23]. - The company aims to launch 10-15 new products over the next two years, maintaining an annual R&D investment of around $1 billion [23]. Abbott - Abbott's strategy emphasizes stable execution, particularly in diabetes management, with plans to expand the FreeStyle Libre system's applications [24]. - The company expects 8%-10% revenue growth in its MedTech business for 2026, focusing on internal innovation and operational efficiency [24]. GE Healthcare - GE Healthcare is shifting its AI capabilities towards standalone software tools, emphasizing the commercialization of AI in imaging [25]. - The company plans to simplify its product offerings to enhance customer experience and reduce internal costs, aiming for organic growth through advanced imaging technologies [25]. Illumina - Illumina's growth strategy focuses on sequencing, multi-omics, and scaling services, with a strong emphasis on partnerships to accelerate drug development [29][30]. - The company aims to maintain a balanced approach between innovation investment and shareholder returns, with a positive outlook for the Chinese market [30]. Edwards Lifesciences - Edwards Lifesciences is focused on structural heart disease, with a commitment to innovation in TAVR and TMTT platforms, expecting 8%-10% sales growth [33][34]. - The company is addressing regulatory challenges while continuing to invest in breakthrough therapies and expanding market access [34]. Jabil - Jabil's CEO discussed the company's transformation and focus on integrating recent acquisitions, with a strategic emphasis on improving sales efficiency in the U.S. market [36][37]. - The company plans to launch new products and leverage AI technology to enhance its offerings in the orthopedic sector [37]. Conclusion - The overall sentiment from the JPM26 conference indicates that major medical device companies are prioritizing alignment of products, organizational structure, and capital utilization to drive growth, rather than focusing solely on new technologies [40].

Core Viewpoint - Shenzhen Lenk Medical Technology Co., Ltd. has completed a multi-million RMB Series A financing round, led by Bangqin Capital, to enhance its high-pressure contrast injection technology and expand its product offerings and international market presence [2]. Market Size and Structure - The global market for high-pressure contrast injectors is projected to reach approximately $2.08 billion in 2024, with consumables accounting for about $1.6 billion and devices around $480 million, expecting a compound annual growth rate (CAGR) of approximately 10.9% from 2025 to 2030 [3]. - In China, the market for high-pressure contrast injectors reached 2.72 billion RMB in 2017, with consumables making up over 60% of the market share, driven by the rapid growth of enhanced CT and interventional imaging [5]. - As of 2023, the market for high-pressure contrast consumables in China has reached 3.97 billion RMB, reflecting a year-on-year growth of 8.4%, with a significant gap in per capita usage compared to the U.S. [6]. Company Overview - Shenzhen Lenk Medical was established in May 2024, focusing on high-pressure contrast and minimally invasive surgical fields, with over 60 intellectual property rights filed or granted [7]. - The company has developed a comprehensive product matrix for high-pressure contrast injectors, including the Nova UC3000 series, which features patented "precise dual-flow mixing" technology for enhanced clinical applications [10]. Team and Engineering Capability - The core team of Lenk Medical comprises members from Mindray Medical and the Chinese Academy of Sciences, possessing extensive experience in electromechanical systems and imaging-related equipment [11]. - Within less than a year, the company has achieved simultaneous progress in R&D, registration, and market expansion, with its devices already in use across multiple provinces and top-tier hospitals [11]. International Expansion - Lenk Medical's products are now available in over 20 countries and regions, with ongoing efforts to build overseas channels and brand recognition through participation in international medical exhibitions [12]. Conclusion - The high-pressure contrast system, while a niche segment within imaging equipment, presents long-term value potential for domestic alternatives due to its technical barriers and clinical integration [13]. The recent financing will support Lenk Medical's continued development in high-pressure contrast technology and its global expansion efforts [13].